Compare Natera Inc. Common Stock (NTRA) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Palantir Technologies Inc — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Palantir Technologies Inc trades at $197.28 (market cap $501.45B). The key difference: Palantir Technologies Inc is far larger — about 8.8× Natera Inc. Common Stock's market cap, and Palantir Technologies Inc is more actively traded (18,438,992 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Palantir Technologies Inc for 79 Days on average.
| NTRA | PLTR | |
|---|---|---|
Market Cap | $57.03B | $501.45B |
Volume | 1,131,157 | 18,438,992 |
Sector | Health | Technology |
52-Week High | $425.64 | $209.05 |
52-Week Low | $179.42 | $107.27 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $56.18B | $492.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Palantir (PLTR) trades at $208.64, down slightly by 0.17% on the day, but maintains strong bullish momentum with the stock near recent highs. The company continues to demonstrate exceptional financial performance with 56.2% revenue growth in 2025, net income margin of 49%, and consistent earnings beats. Recent partnership with Armada for sovereign AI infrastructure highlights ongoing business expansion. Technical indicators show strong bullish sentiment with the stock trading above key support levels.
Palantir presents a compelling growth story with accelerating revenue and profitability, though premium valuations require continued execution. The stock faces risks from high expectations and potential growth deceleration, but strong institutional support and AI leadership provide upside potential. Current analyst consensus suggests moderate upside from current levels with 54% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
